All In Biotech

Drug Trial Radar · NCT02002247

SodiUm SeleniTe Adminstration IN Cardiac Surgery (SUSTAIN CSX®-Trial).

SodiUm SeleniTe Adminstration IN Cardiac Surgery (SUSTAIN CSX®-Trial). A Multicentre Randomized Controlled Trial of High Dose Sodium-selenite Administration in High Risk Cardiac Surgical Patients

Last checked: Nov 20, 2026Latest source record: Jun 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 1,400 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

1,400

Planned (sponsor's estimate)

Start

Jan 2015

Primary completion

Feb 2021

Study completion Jul 2021

Sponsor

Lead sponsor
Daren K. HeylandAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
biosyn Arzneimittel GmbH; Queen's University; RWTH Aachen University
First posted
Dec 5, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of the investigators' research program is to investigate the effects of perioperative high dose selenium supplementation in high-risk cardiac surgical patients undergoing complicated open heart surgery. The investigators hypothesize that the therapeutic strategy tested in this randomized trial may contribute to a fewer complications, less organ injury and fewer deaths. Before the investigators conducted the large definitive trial, they conducted a pilot study to assess the feasibility of the protocol, and are rolling the pilot patients into the definitive trial.

Conditions

  • Heart Disease

Interventions

  • sodium seleniteDrug

    All subjects will receive an IV bolus of 2000µg selenium within 30min after induction of anesthesia via the central venous catheter. After termination of surgery, immediately after admission to the ICU, all patients will receive a second bolus of 2000µg selenium. Then on every further morning during ICU-stay, patients will receive an IV bolus of 1000µg selenium via central or peripheral venous access until death, discharge from ICU to the ward, or for a maximum of 10 days.

  • PlaceboDrug

    All patients will receive an IV bolus of normal saline (equals to 40ml prepared solution) within 30min after induction of anesthesia via the central venous catheter. After termination of surgery, immediately after admission to the ICU, all patients will receive a second bolus of normal saline accordingly. Then on every further morning during ICU-stay, patients will receive an IV bolus of normal saline via central or peripheral venous access until death, discharge from ICU to the ward (treatment may continue in a step down or intermediate care unit), or for a maximum of 10 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PODS free days + aliveTime frame: 30 Day

Locations

23 sites in 2 countries. Site status is shown where the registry gives one.

  • Hamilton General Hospital

    Hamilton, Ontario, Canada

  • London Health Sciences Centre

    London, Ontario, Canada

  • University of Ottawa Heart Institute

    Ottawa, Ontario, Canada

  • Sunnybrook Health Sciences Centre

    Toronto, Ontario, Canada

  • St. Michael's Hospital

    Toronto, Ontario, Canada

  • Toronto General Hospital

    Toronto, Ontario, Canada

  • Institut de cardiologie de Montreal

    Montreal, Quebec, Canada

  • Sir Mortimer B. Davis Jewish General Hospital

    Montreal, Quebec, Canada

  • McGill University Health Centre

    Montreal, Quebec, Canada

  • Sacre Coeur

    Montreal, Quebec, Canada

  • IUCPQ

    Québec, Quebec, Canada

  • Centre de recherche CIUSSS de l'Estrie CHUS

    Sherbrooke, Quebec, Canada

  • RWTH Aachen University Hospital

    Aachen, Germany

  • Klinik und Poliklinik für Anästhesiologie und Operative Intensivmedizin Universitätsklinikum Bonn

    Bonn, Germany

  • Klinik und Poliklinik für Herz- und Thoraxchirurgie Uniklinik Köln

    Cologne, Germany

  • Universitätsklinikum Frankfurt

    Frankfurt, Germany

  • Klinik für Her- und Gefäßchirurgie Universitäts-Herzzentrum Freiburg

    Freiburg im Breisgau, Germany

  • Klinik für Herz-, Kinderherz- und Gefäßchirurgie UKGM Giessen

    Giessen, Germany

  • University Medical Center Schleswig-Holstein

    Kiel, Germany

  • Klinik für Anästhesiologie Universitätsmedizin Mainz

    Mainz, Germany

  • Klinik für Anästhesiologie Klinikum der Universität München

    München, Germany

  • Klinik für Anästhesiologie, operative Intensivmedizin und Schmerztherapie Universitätsmedizin Münster, Zentralklinikum

    Münster, Germany

  • Klinikum Oldenburg gGmbH Universitätsklinik für Anästhesiologie / Intensivmedizin / Notfallmedizin / Schmerztherapie

    Oldenburg, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.